FMA is a nanotechnology based intradermal drug-delivery system. The core of the system is a disposable drug patch which contains therapeutic agents or vaccines. Once the device is applied on skin, it creates nanoscale channels through which a variety of drugs or vaccines released from drug patch can be delivered effectively in a painless way for an extended period of time. Our pre-clinical data demonstrates that more than 10,000 fold enhancement in percutaneous drug delivery can be achieved for both small and large drug molecules by using the FMA drug delivery

system. Nanomed owns or has worldwide exclusive licensing rights on one issued and nine pending patent applications in US, China and the rest of the world.

FMA technology is unique. Unlike other injectables or conventional transdermal systems, Nanomed's therapeutic patches are adaptable for use with a wide range of medications and yield benefits that set products apart from the competitors. Our patches are small, comfortable and adherent, and maintain reproducible blood levels.

Nanomed's patents, which extend protection through 2023 and beyond, presents significant developmental barriers to competitors who generally are left to modified transdermal systems. The result is often a less efficient, less desirable patch product.

Benefits:

Nanomed FMA system has the ability to revolutionize the drug delivery for small and large drug molecules, as well as vaccins. Our system has significant advantages over current injectables or conventional transdermal systems, including:

1. Reduced pain perception, thus increase patient compliance and convenience

2. Improved pharmacokinetic and bioavailability profiles

     Provide once-daily to once-weekly delivery systems with steady drug action
     Eliminate first-pass metabolism
     Introduce less drug into the body to achieve therapeutic blood levels with less side effects
     Reduce food and systemic drug interactions and associated side effects
     Permit flexibility of dose duration via patch removal

3. For pharmaceutical companies, our system provides them an ideal platform for extending
    their existing product's life cycle because FMA technology is patented through 2023
    and beyond.